|Other names||Morbilli, rubeola, red measles, English measles|
|A child showing a day-four measles rash|
|Symptoms||Fever, cough, runny nose, inflamed eyes, rash|
|Complications||Pneumonia, seizures, encephalitis, subacute sclerosing panencephalitis, immunosuppression|
|Usual onset||10–12 days after exposure|
|Frequency||20 million per year|
Measles is a highly contagious infectious disease caused by the measles virus. Symptoms usually develop 10–12 days after exposure to an infected person and last 7–10 days. Initial symptoms typically include fever, often greater than 40 °C (104 °F), cough, runny nose, and inflamed eyes. Small white spots known as Koplik's spots may form inside the mouth two or three days after the start of symptoms. A red, flat rash which usually starts on the face and then spreads to the rest of the body typically begins three to five days after the start of symptoms. Common complications include diarrhea (in 8% of cases), middle ear infection (7%), and pneumonia (6%). These occur in part due to measles-induced immunosuppression. Less commonly seizures, blindness, or inflammation of the brain may occur. Other names include morbilli, rubeola, red measles, and English measles. Both rubella, also known as "German measles", and roseola are different diseases caused by unrelated viruses.
Measles is an airborne disease which spreads easily through the coughs and sneezes of infected people. It may also be spread through direct contact with mouth or nasal secretions. Nine out of ten people who are not immune and share living space with an infected person will be infected. People are infectious to others from four days before to four days after the start of the rash. Most people do not get the disease more than once. Testing for the measles virus in suspected cases is important for public health efforts.
The measles vaccine is effective at preventing the disease, and is often delivered in combination with other vaccines. Vaccination resulted in a 80% decrease in deaths from measles between 2000 and 2017, with about 85% of children worldwide having received their first dose as of 2017. Once a person has become infected, no specific treatment is available, although supportive care may improve outcomes. Such care may include oral rehydration solution (slightly sweet and salty fluids), healthy food, and medications to control the fever. Antibiotics should be prescribed if secondary bacterial infections such as ear infections or pneumonia occur. Vitamin A supplementation is also recommended for children.
Measles affects about 20 million people a year, primarily in the developing areas of Africa and Asia. While often regarded as a childhood illness, it can affect people of any age. It is one of the leading vaccine-preventable disease causes of death. In 1980, 2.6 million people died of it, and in 1990, 545,000 died; by 2014, global vaccination programs had reduced the number of deaths from measles to 73,000. Despite these trends, rates of disease and deaths increased from 2017 to 2019 due to a decrease in immunization. The risk of death among those infected is about 0.2%, but may be up to 10% in people with malnutrition. Most of those who die from the infection are less than five years old. Measles is not known to occur in other animals.
- 1 Signs and symptoms
- 2 Cause
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Treatment
- 7 Prognosis
- 8 Epidemiology
- 9 History
- 10 Society and culture
- 11 Research
- 12 References
- 13 External links
Signs and symptoms
Symptoms typically begin 10–14 days after exposure. The classic symptoms include a four-day fever (the 4 D's) and the three C's—cough, coryza (head cold, fever, sneezing), and conjunctivitis (red eyes)—along with a maculopapular rash. Fever is common and typically lasts for about one week; the fever seen with measles is often as high as 40 °C (104 °F).
Koplik's spots seen inside the mouth are diagnostic for measles, but are temporary and therefore rarely seen. Koplik spots are small white spots that are commonly seen on the inside of the cheeks opposite the molars. They appear as "grains of salt on a reddish background." Recognizing these spots before a person reaches their maximum infectiousness can help reduce the spread of the disease.
The characteristic measles rash is classically described as a generalized red maculopapular rash that begins several days after the fever starts. It starts on the back of the ears and, after a few hours, spreads to the head and neck before spreading to cover most of the body, often causing itching. The measles rash appears two to four days after the initial symptoms and lasts for up to eight days. The rash is said to "stain", changing color from red to dark brown, before disappearing. Overall, measles usually resolves after about three weeks.
Complications of measles are relatively common, ranging from mild ones such as diarrhea to serious ones such as pneumonia (either direct viral pneumonia or secondary bacterial pneumonia), laryngotracheobronchitis (croup) (either direct viral laryngotracheobronchitis or secondary bacterial bronchitis), otitis media, acute brain inflammation (and very rarely subacute sclerosing panencephalitis), and corneal ulceration (leading to corneal scarring). In addition, measles can suppress the immune system for weeks to months, and this can contribute to bacterial superinfections such as otitis media and bacterial pneumonia.
The death rate in the 1920s was around 30% for measles pneumonia. People who are at high risk for complications are infants and children aged less than 5 years; adults aged over 20 years; pregnant women; people with compromised immune systems, such as from leukemia, HIV infection or innate immunodeficiency; and those who are malnourished or have Vitamin A deficiency. Complications are usually more severe in adults who catch the virus. Between 1987 and 2000, the case fatality rate across the United States was three deaths per 1,000 cases attributable to measles, or 0.3%. In underdeveloped nations with high rates of malnutrition and poor healthcare, fatality rates have been as high as 28%. In immunocompromised persons (e.g., people with AIDS) the fatality rate is approximately 30%.
Even in previously healthy children, measles can cause serious illness requiring hospitalization. One out of every 1,000 measles cases progresses to acute encephalitis, which often results in permanent brain damage. One or two out of every 1,000 children who become infected with measles will die from respiratory and neurological complications.
The virus is highly contagious and is spread by coughing and sneezing via close personal contact or direct contact with secretions. It can live for up to two hours in that airspace or nearby surfaces. Measles is so contagious that if one person has it, 90% of nearby non-immune people will also become infected. Humans are the only natural hosts of the virus, and no other animal reservoirs are known to exist.
Risk factors for measles virus infection include immunodeficiency caused by HIV or AIDS, immunosuppression following receipt of an organ or a stem cell transplant, alkylating agents, or corticosteroid therapy, regardless of immunization status; travel to areas where measles commonly occurs or contact with travelers from such an area; and the loss of passive, inherited antibodies before the age of routine immunization.
Once the measles virus gets onto the mucosa, it infects the epithelial cells in the trachea or bronchi. Measles virus uses a protein on its surface called hemagglutinin (H protein), to bind to a target receptor on the host cell, which could be CD46, which is expressed on all nucleated human cells, CD150, aka signaling lymphocyte activation molecule or SLAM, which is found on immune cells like B or T cells, and antigen-presenting cells, or nectin-4, a cellular adhesion molecule. Once bound, the fusion, or F protein helps the virus fuse with the membrane and ultimately get inside the cell. The virus is a single-stranded negative-sense RNA virus meaning it first has to be transcribed by RNA polymerase into a positive-sense mRNA strand.
After that it is ready to be translated into viral proteins, wrapped in the cell's lipid envelope, and sent out of the cell as a newly made virus. Within days, the measles virus spreads through local tissue and is picked up by dendritic cells and alveolar macrophages, and carried from that local tissue in the lungs to the local lymph nodes. From there it continues to spread, eventually getting into the blood and spreading to more lung tissue, as well as other organs like the intestines and the brain. Functional impairment of the infected dendritic cells by the measles virus is thought to contribute to measles-induced immunosuppression.
Clinical diagnosis of measles requires a history of fever of at least three days, with at least one of the following symptoms: cough, coryza, or conjunctivitis. Observation of Koplik's spots is also diagnostic. Laboratory confirmation is however strongly recommended.
Laboratory diagnosis of measles can be done with confirmation of positive measles IgM antibodies or isolation of measles virus RNA from respiratory specimens. For people unable to have their blood drawn, saliva can be collected for salivary measles-specific IgA testing. Positive contact with other people known to have measles adds evidence to the diagnosis.
Mothers who are immune to measles pass antibodies to their children while they are still in the womb, especially if the mother acquired immunity through infection rather than vaccination. Such antibodies will usually give newborn infants some immunity against measles, but these antibodies are gradually lost over the course of the first nine months of life. Infants under one year of age whose maternal anti-measles antibodies have disappeared become susceptible to infection with the measles virus.
In developed countries, it is recommended that children be immunized against measles at 12 months, generally as part of a three-part MMR vaccine (measles, mumps, and rubella). The vaccine is generally not given before this age because such infants respond inadequately to the vaccine due to an immature immune system. A second dose of the vaccine is usually given to children between the ages of four and five, to increase rates of immunity. Vaccination rates have been high enough to make measles relatively uncommon. Adverse reactions to vaccination are rare, with fever and pain at the injection site being the most common. Life-threatening adverse reactions occur in less than one per million vaccinations (<0.0001%).
In developing countries where measles is common, the World Health Organization (WHO) recommends two doses of vaccine be given, at six and nine months of age. The vaccine should be given whether the child is HIV-infected or not. The vaccine is less effective in HIV-infected infants than in the general population, but early treatment with antiretroviral drugs can increase its effectiveness. Measles vaccination programs are often used to deliver other child health interventions as well, such as bed nets to protect against malaria, antiparasite medicine and vitamin A supplements, and so contribute to the reduction of child deaths from other causes.
The Advisory Committee on Immunization Practices (ACIP) recommends that all adult international travelers who do not have positive evidence of previous measles immunity receive two doses of MMR vaccine before traveling. Those born in the United States before 1957 are presumed to be immune because they would have had the disease in their childhood before any vaccination was available.
There have been false claims of an association between the measles vaccine and autism; this incorrect concern has reduced the rate of vaccination and increased the number of cases of measles where immunisation rates became too low to maintain herd immunity.
There is no specific antiviral treatment if measles develops. Instead the medications are generally aimed at treating superinfections, maintaining good hydration with adequate fluids, and pain relief. Some groups, like young children and the severely malnourished, are also given vitamin A, which act as an immunomodulator that boosts the antibody responses to measles and decreases the risk of serious complications.
Treatment is supportive, with ibuprofen or paracetamol (acetaminophen) to reduce fever and pain and, if required, a fast-acting medication to dilate the airways for cough. As for aspirin, some research has suggested a correlation between children who take aspirin and the development of Reye syndrome.
The use of vitamin A during treatment is recommended to decrease the risk of blindness; however, it does not prevent or cure the disease. A systematic review of trials into its use found no reduction in overall mortality, but it did reduce mortality in children aged under two years. It is unclear if zinc supplementation in children with measles affects outcomes as it has not been sufficiently studied.
Most people survive measles, though in some cases, complications may occur. About 1 in 4 individuals will be hospitalized and 1-2 in 1000 will die. Complications are more likely in children under age 5 and adults over age 20.
Possible consequences of measles virus infection include laryngotracheobronchitis, sensorineural hearing loss, and—in about 1 in 10,000 to 1 in 300,000 cases—panencephalitis, which is usually fatal. Acute measles encephalitis is another serious risk of measles virus infection. It typically occurs two days to one week after the measles rash breaks out and begins with very high fever, severe headache, convulsions and altered mentation. A person with measles encephalitis may become comatose, and death or brain injury may occur.
For people having had measles, it is rare to ever have a symptomatic reinfection.
Measles is extremely infectious and its continued circulation in a community depends on the generation of susceptible hosts by birth of children. In communities that generate insufficient new hosts the disease will die out. This concept was first recognized in measles by Bartlett in 1957, who referred to the minimum number supporting measles as the critical community size (CCS). Analysis of outbreaks in island communities suggested that the CCS for measles is around 250,000. To achieve herd immunity, more than 95% of the community must be vaccinated due to the ease with which measles is transmitted from person to person.
In 2011, the WHO estimated that 158,000 deaths were caused by measles. This is down from 630,000 deaths in 1990. As of 2018, measles remains a leading cause of vaccine-preventable deaths in the world. In developed countries the mortality rate is lower, for example in England and Wales from 2007-2017 death occurred between two and three cases out of 10,000. In children one to two cases out of every 1,000 die in the United States (0.1–0.2%). In populations with high levels of malnutrition and a lack of adequate healthcare, mortality can be as high as 10%. In cases with complications, the rate may rise to 20–30%.[medical citation needed] In 2012, the number of deaths due to measles was 78% lower than in 2000 due to increased rates of immunization among UN member states.
|Region of the Americas||257,790||218,579||1,755||66||19,898|
|Eastern Mediterranean Region||341,624||59,058||38,592||15,069||28,031|
|South-East Asia Region||199,535||224,925||61,975||83,627||112,418|
|Western Pacific Region||1,319,640||155,490||176,493||128,016||213,366|
Even in countries where vaccination has been introduced, rates may remain high. Measles is a leading cause of vaccine-preventable childhood mortality. Worldwide, the fatality rate has been significantly reduced by a vaccination campaign led by partners in the Measles Initiative: the American Red Cross, the United States CDC, the United Nations Foundation, UNICEF and the WHO. Globally, measles fell 60% from an estimated 873,000 deaths in 1999 to 345,000 in 2005. Estimates for 2008 indicate deaths fell further to 164,000 globally, with 77% of the remaining measles deaths in 2008 occurring within the Southeast Asian region.
Cases reported in the first three months of 2019 were 300% higher than in the first three months of 2018, with outbreaks in every region of the world, even in countries with high overall vaccination coverage where it spread among clusters of unvaccinated people.
In 2013–14, there were almost 10,000 cases in 30 European countries. Most cases occurred in unvaccinated individuals and over 90% of cases occurred in Germany, Italy, Netherlands, Romania, and United Kingdom. Between October 2014 and March 2015, a measles outbreak in the German capital of Berlin resulted in at least 782 cases. In 2017, numbers continued to increase in Europe to 21,315 cases, with 35 deaths. In preliminary figures for 2018, reported cases in the region increased 3-fold to 82,596 in 47 countries, with 72 deaths; Ukraine had the most cases (53,218), with the highest incidence rates being in Ukraine (1209 cases per million), Serbia (579), Georgia (564) and Albania (500). The previous year (2017) saw an estimated measles vaccine coverage of 95% for the first dose and 90% for the second dose in the region, the latter figure being the highest-ever estimated second-dose coverage.
In 2019 the United Kingdom, Albania, the Czech Republic, and Greece lost their measles free status due to ongoing and prolonged spread of the disease in these countries. In the first 6 months of 2019 90,000 cases occurred in Europe.
In the United States, measles affected approximately 3,000 people per million in the 1960s before the vaccine was available. With consistent widespread childhood vaccination, this figure fell to 13 cases per million by the 1980s, and to about 1 case per million by the year 2000.
Before immunization in the United States, between three and four million cases occurred each year. The United States was declared free of circulating measles in 2000, with 911 cases from 2001 to 2011. In 2014 the CDC said endemic measles, rubella, and congenital rubella syndrome had not returned to the United States. Occasional measles outbreaks persist, however, because of cases imported from abroad, of which more than half are the result of unvaccinated U.S. residents who are infected abroad and infect others upon return to the United States. The CDC continues to recommend measles vaccination throughout the population to prevent outbreaks like these.
In 2014, an outbreak was initiated in Ohio when two unvaccinated Amish men harboring asymptomatic measles returned to the United States from missionary work in the Philippines. Their return to a community with low vaccination rates led to an outbreak that rose to include a total of 383 cases across nine counties. Of the 383 cases, 340 (89%) occurred in unvaccinated individuals.
From 4 January to 2 April 2015, there were 159 cases of measles reported to the CDC. Of those 159 cases, 111 (70%) were determined to have come from an earlier exposure in late December 2014. This outbreak was believed to have originated from the Disneyland theme park in California. The Disneyland outbreak was held responsible for the infection of 147 people in seven U.S. states as well as Mexico and Canada, the majority of which were either unvaccinated or had unknown vaccination status. Of the cases 48% were unvaccinated and 38% were unsure of their vaccination status. The initial exposure to the virus was never identified.
In 2015, a U.S. woman in Washington state died of pneumonia, as a result of measles. She was the first fatality in the U.S. from measles since 2003. The woman had been vaccinated for measles and was taking immunosuppressive drug for another condition. The drugs suppressed the woman's immunity to measles, and the woman became infected with measles; she did not develop a rash, but contracted pneumonia, which caused her death.
In June 2017, the Maine Health and Environmental Testing Laboratory confirmed a case of measles in Franklin County. This instance marks the first case of measles in 20 years for the state of Maine. In 2018 one case occurred in Portland, Oregon, with 500 people exposed; 40 of them lacked immunity to the virus and were being monitored by county health officials as of 2 July 2018. There were 273 cases of measles reported throughout the United States in 2018, including an outbreak in Brooklyn with more than 200 reported cases from October 2018 to February 2019. The outbreak was tied with population density of the Orthodox Jewish community, with the initial exposure from an unvaccinated child that caught measles while visiting Israel.
A resurgence of measles occurred during 2019, which has been generally tied to parents choosing not to have their children vaccinated as most of the reported cases have occurred in people 19 years old or younger. Cases were first reported in Washington state in January, with an outbreak of at least 58 confirmed cases most within Clark County, which has a higher rate of vaccination exemptions compared to the rest of the state; nearly one in four kindergartners in Clark did not receive vaccinations, according to state data. This led state governor Jay Inslee to declare a state of emergency, and the state's congress to introduce legislation to disallow vaccination exemption for personal or philosophical reasons. In April 2019, New York Mayor Bill de Blasio declared a public health emergency because of "a huge spike" in cases of measles where there were 285 cases centred on the Orthodox Jewish areas of Brooklyn in 2018, while there were only two cases in 2017. There were 168 more in neighboring Rockland County. Other outbreaks have included Santa Cruz County and Butte County in California, and the states of New Jersey and Michigan. As of April 2019[update], there have been 695 cases of measles reported in 22 states. This is the highest number of measles cases since it was declared eradicated in 2000. From 1 January to 3 October 2019, 1,250 individual cases of measles have been confirmed in 31 states. This is the greatest number of cases reported in the U.S. since 1992. Of the 1,250 cases, 119 of the people who got measles were hospitalized, and 61 reported having complications, including pneumonia and encephalitis.
Brazil won a measles elimination certificate by the Pan American Health Organization in 2016, but the Ministry of Health has proclaimed that the country has struggled to keep this certificate, since two outbreaks had already been identified in 2018, one in the state of Amazonas and another one in Roraima, in addition to cases in other states (Rio de Janeiro, Rio Grande do Sul, Pará, São Paulo and Rondônia), totaling 1053 confirmed cases until 1 August 2018. In these outbreaks, and in most other cases, the contagion was related to the importation of the virus, especially from Venezuela. This was confirmed by the genotype of the virus (D8) that was identified, which is the same that circulates in Venezuela.
In the Vietnamese measles epidemic in spring of 2014, an estimated 8,500 measles cases were reported as of 19 April, with 114 fatalities; as of 30 May, 21,639 suspected measles cases had been reported, with 142 measles-related fatalities. In the Naga Self-Administered Zone in a remote northern region of Myanmar, at least 40 children died during a measles outbreak in August 2016 that was probably caused by lack of vaccination in an area of poor health infrastructure. Following the 2019 Philippines measles outbreak, 23,563 measles cases have been reported in the country with 338 fatalities. A measles outbreak also happened among the Malaysian Orang Asli sub-group of Batek people in the state of Kelantan from May 2019, causing the deaths of 15 from the tribe.
Estimates based on modern molecular biology place the emergence of measles as a human disease sometime after 500 AD (the former speculation that the Antonine Plague of 165–180 AD was caused by measles is now discounted). The first systematic description of measles, and its distinction from smallpox and chickenpox, is credited to the Persian physician Rhazes (860–932), who published The Book of Smallpox and Measles. Given what is now known about the evolution of measles, Rhazes' account is remarkably timely, as recent work that examined the mutation rate of the virus indicates the measles virus emerged from rinderpest (cattle plague) as a zoonotic disease between 1100 and 1200 AD, a period that may have been preceded by limited outbreaks involving a virus not yet fully acclimated to humans. This agrees with the observation that measles requires a susceptible population of >500,000 to sustain an epidemic, a situation that occurred in historic times following the growth of medieval European cities.
Measles is an endemic disease, meaning it has been continually present in a community, and many people develop resistance. In populations not exposed to measles, exposure to the new disease can be devastating. In 1529, a measles outbreak in Cuba killed two-thirds of those natives who had previously survived smallpox. Two years later, measles was responsible for the deaths of half the population of Honduras, and it had ravaged Mexico, Central America, and the Inca civilization.
Between roughly 1855 and 2005, measles has been estimated to have killed about 200 million people worldwide. Measles killed 20 percent of Hawaii's population in the 1850s. In 1875, measles killed over 40,000 Fijians, approximately one-third of the population. In the 19th century, the disease killed 50% of the Andamanese population. Seven to eight million children are thought to have died from measles each year before the vaccine was introduced.
In 1954, the virus causing the disease was isolated from a 13-year-old boy from the United States, David Edmonston, and adapted and propagated on chick embryo tissue culture. To date, 21 strains of the measles virus have been identified. While at Merck, Maurice Hilleman developed the first successful vaccine. Licensed vaccines to prevent the disease became available in 1963. An improved measles vaccine became available in 1968. Measles as an endemic disease was eliminated from the United States in 2000, but continues to be reintroduced by international travelers.
Society and culture
German anti-vaccination campaigner and HIV/AIDS denialist Stefan Lanka posed a challenge on his website in 2011, offering a sum of €100,000 for anyone who could scientifically prove that measles is caused by a virus and determine the diameter of the virus. He posits that the illness is psychosomatic and that the measles virus does not exist. When provided with overwhelming scientific evidence from various medical studies by German physician David Bardens, Lanka did not accept the findings, forcing Bardens to appeal in court. The legal case ended with the ruling that Lanka was to pay the prize. The case received wide international coverage that prompted many to comment on it, including neurologist, well-known skeptic and science-based medicine advocate Steven Novella, who called Lanka "a crank".
As outbreaks easily occur in under-vaccinated populations, the disease is seen as a test of sufficient vaccination within a population.
In May 2015, the journal Science published a report in which researchers found that the measles infection can leave a population at increased risk for mortality from other diseases for two to three years. Results from additional studies that show the measles virus can kill cells that make antibodies were published in November 2019.
- Milner DA (2015). Diagnostic Pathology: Infectious Diseases E-Book. Elsevier Health Sciences. p. 24. ISBN 9780323400374. Archived from the original on 8 September 2017.
- Stanley J (2002). Essentials of Immunology & Serology. Cengage Learning. p. 323. ISBN 978-0766810648. Archived from the original on 8 September 2017.
- Caserta, MT, ed. (September 2013). "Measles". Merck Manual Professional. Merck Sharp & Dohme Corp. Archived from the original on 23 March 2014. Retrieved 23 March 2014.
- "Measles (Rubeola) Signs and Symptoms". Centers for Disease Control and Prevention (CDC). 3 November 2014. Archived from the original on 2 February 2015. Retrieved 5 February 2015.
- Atkinson W (2011). Epidemiology and Prevention of Vaccine-Preventable Diseases (12 ed.). Public Health Foundation. pp. 301–23. ISBN 9780983263135. Archived from the original on 7 February 2015. Retrieved 5 February 2015.
- Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL (July 2016). "Measles". Nature Reviews. Disease Primers. 2: 16049. doi:10.1038/nrdp.2016.49. PMID 27411684.
- "Measles Fact sheet N°286". World Health Organization (WHO). November 2014. Archived from the original on 3 February 2015. Retrieved 4 February 2015.
- Conn's Current Therapy 2015. Elsevier Health Sciences. 2014. p. 153. ISBN 9780323319560. Archived from the original on 8 September 2017.
- GBD 2015 Mortality and Causes of Death Collaborators (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
- "Measles (Red Measles, Rubeola)". Dept of Health, Saskatchewan. Archived from the original on 10 February 2015. Retrieved 10 February 2015.
- Marx JA (2010). Rosen's emergency medicine: concepts and clinical practice (7th ed.). Philadelphia: Mosby/Elsevier. p. 1541. ISBN 9780323054720. Archived from the original on 8 September 2017.
- "Measles". World Health Organization (WHO). Retrieved 20 May 2019.
- Chen S.S.P. (22 February 2018). Measles (Report). Medscape. Archived from the original on 25 September 2011.
- Kabra SK, Lodha R (August 2013). "Antibiotics for preventing complications in children with measles". The Cochrane Database of Systematic Reviews. 8 (8): CD001477. doi:10.1002/14651858.CD001477.pub4. PMID 23943263.
- "Despite the availability of a safe, effective and inexpensive vaccine for more than 40 years, measles remains a leading vaccine-preventable cause of childhood deaths" (PDF). Retrieved 16 February 2019.
- GBD 2013 Mortality Causes of Death Collaborators (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
- "Measles cases spike globally due to gaps in vaccination coverage". World Health Organization (WHO). 29 November 2018. Retrieved 21 December 2018.
- "U.S. measles cases surge nearly 20 percent in early April, CDC says". Reuters. 16 April 2019. Retrieved 16 April 2019.
- "Measles – European Region". World Health Organization (WHO). Retrieved 8 May 2019.
- "Pinkbook Measles Epidemiology of Vaccine Preventable Diseases". Centers for Disease Control and Prevention (CDC). 15 November 2016. Retrieved 6 May 2018.
- "Measles". Merck Manuals Professional Edition. January 2018. Retrieved 6 May 2018.
- Biesbroeck L, Sidbury R (November 2013). "Viral exanthems: an update". Dermatologic Therapy. 26 (6): 433–8. doi:10.1111/dth.12107. PMID 24552405.
- Ludlow M, McQuaid S, Milner D, de Swart RL, Duprex WP (January 2015). "Pathological consequences of systemic measles virus infection". The Journal of Pathology. 235 (2): 253–65. doi:10.1002/path.4457. PMID 25294240.
- Steichen O, Dautheville S (March 2009). "Koplik spots in early measles". CMAJ. 180 (5): 583. doi:10.1503/cmaj.080724. PMC 2645467. PMID 19255085.
- Baxby D (July 1997). "The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal mucous membraneBy Henry Koplik, M.D. Reproduced from Arch. Paed. 13, 918-922 (1886)". Reviews in Medical Virology. 7 (2): 71–74. doi:10.1002/(SICI)1099-1654(199707)7:2<71::AID-RMV185>3.0.CO;2-S. PMID 10398471.
- "Symptoms of measles". National Health Service (NHS). 26 January 2010. Archived from the original on 31 January 2011.CS1 maint: unfit url (link)
- Gardiner, W. T. (2007). "Otitis Media in Measles". The Journal of Laryngology & Otology. 39 (11): 614–17. doi:10.1017/S0022215100026712.
- Fisher DL, Defres S, Solomon T (March 2015). "Measles-induced encephalitis". QJM. 108 (3): 177–82. doi:10.1093/qjmed/hcu113. PMID 24865261.
- Anlar B (2013). "Subacute sclerosing panencephalitis and chronic viral encephalitis". Pediatric Neurology Part II. Handbook of Clinical Neurology. 112. pp. 1183–89. doi:10.1016/B978-0-444-52910-7.00039-8. ISBN 9780444529107. PMID 23622327.
- Semba RD, Bloem MW (March 2004). "Measles blindness". Survey of Ophthalmology. 49 (2): 243–55. doi:10.1016/j.survophthal.2003.12.005. PMID 14998696.
- Gupta P, Menon PS, Ramji S, Lodha R, Rakesh (2015). PG Textbook of Pediatrics: Volume 2: Infections and Systemic Disorders. JP Medical Ltd. p. 1158. ISBN 9789351529552.
- Griffin DE (July 2010). "Measles virus-induced suppression of immune responses". Immunological Reviews. 236: 176–89. doi:10.1111/j.1600-065X.2010.00925.x. PMC 2908915. PMID 20636817.
- Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL (July 2016). "Measles". Nature Reviews. Disease Primers. 2: 16049. doi:10.1038/nrdp.2016.49. PMID 27411684.
- Ellison JB (February 1931). "Pneumonia in Measles". Archives of Disease in Childhood. 6 (31): 37–52. doi:10.1136/adc.6.31.37. PMC 1975146. PMID 21031836.
- "Measles". Centers for Disease Control and Prevention (CDC). Archived from the original on 23 October 2016. Retrieved 22 October 2016.
- National Institutes of Health Office of Dietary Supplements (2013). "Vitamin A". U.S. Department of Health & Human Services. Archived from the original on 11 March 2015. Retrieved 11 March 2015.
- Sabella C (March 2010). "Measles: not just a childhood rash". Cleveland Clinic Journal of Medicine. 77 (3): 207–13. doi:10.3949/ccjm.77a.09123. PMID 20200172.
- Perry RT, Halsey NA (May 2004). "The clinical significance of measles: a review". The Journal of Infectious Diseases. 189 Suppl 1 (S1): S4–16. doi:10.1086/377712. PMID 15106083.
- Sension MG, Quinn TC, Markowitz LE, Linnan MJ, Jones TS, Francis HL, et al. (December 1988). "Measles in hospitalized African children with human immunodeficiency virus". American Journal of Diseases of Children. 142 (12): 1271–2. doi:10.1001/archpedi.1988.02150120025021. PMID 3195521.
- Cohen BE, Durstenfeld A, Roehm PC (July 2014). "Viral causes of hearing loss: a review for hearing health professionals". Trends in Hearing. 18: 2331216514541361. doi:10.1177/2331216514541361. PMC 4222184. PMID 25080364.
- "Measles". Centers for Disease Control and Prevention (CDC). 2 April 2018. Retrieved 6 May 2018.
- Gowda VK, Sukanya V (November 2012). "Acquired immunodeficiency syndrome with subacute sclerosing panencephalitis". Pediatric Neurology. 47 (5): 379–81. doi:10.1016/j.pediatrneurol.2012.06.020. PMID 23044024.
- Waggoner JJ, Soda EA, Deresinski S (October 2013). "Rare and emerging viral infections in transplant recipients". Clinical Infectious Diseases. 57 (8): 1182–8. doi:10.1093/cid/cit456. PMID 23839998.
- Leuridan E, Sabbe M, Van Damme P (September 2012). "Measles outbreak in Europe: susceptibility of infants too young to be immunized". Vaccine. 30 (41): 5905–13. doi:10.1016/j.vaccine.2012.07.035. PMID 22841972.
- Moss WJ, Griffin DE (January 2012). "Measles". Lancet. 379 (9811): 153–64. doi:10.1016/S0140-6736(10)62352-5. PMID 21855993.
- Textbook of Microbiology & Immunology. Elsevier India. 2009. p. 535. ISBN 9788131221631.
- Kaslow RA, Stanberry LR, Le Duc JW (2014). Viral Infections of Humans: Epidemiology and Control. Springer. p. 540. ISBN 9781489974488.
- Schaechter's Mechanisms of Microbial Disease. Lippincott Williams & Wilkins. 2012. p. 357. ISBN 9780781787444.
- "Measles". Centers for Disease Control and Prevention (CDC). 2 April 2018. Retrieved 8 May 2018.
- Durrheim DN, Kelly H, Ferson MJ, Featherstone D (August 2007). "Remaining measles challenges in Australia". The Medical Journal of Australia. 187 (3): 181–4. doi:10.5694/j.1326-5377.2007.tb01182.x. PMID 17680748. Archived from the original on 2 April 2015.
- Friedman M, Hadari I, Goldstein V, Sarov I (October 1983). "Virus-specific secretory IgA antibodies as a means of rapid diagnosis of measles and mumps infection". Israel Journal of Medical Sciences. 19 (10): 881–4. PMID 6662670.
- Galindo BM, Concepción D, Galindo MA, Pérez A, Saiz J (January 2012). "Vaccine-related adverse events in Cuban children, 1999-2008". MEDICC Review. 14 (1): 38–43. PMID 22334111. Archived from the original on 24 February 2012.
- Helfand RF, Witte D, Fowlkes A, Garcia P, Yang C, Fudzulani R, et al. (November 2008). "Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi". The Journal of Infectious Diseases. 198 (10): 1457–65. doi:10.1086/592756. PMID 18828743.
- Ołdakowska A, Marczyńska M (2008). "[Measles vaccination in HIV infected children]". Medycyna Wieku Rozwojowego. 12 (2 Pt 2): 675–80. PMID 19418943.
- "Global goal to reduce measles deaths in children surpassed" (Press release). UNICEF. 2007. Archived from the original on 4 February 2015. Retrieved 11 March 2015.
- McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS (June 2013). "Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Recommendations and Reports. 62 (RR-04): 1–34. PMID 23760231.
- "Measles vaccines: WHO position paper – April 2017" (PDF). Releve Epidemiologique Hebdomadaire. 92 (17): 205–27. April 2017. PMID 28459148.
- Rezaie SR. "Measles: The Sequel". Emergency Physicians Monthly. Retrieved 7 June 2019.
- Casteels-Van Daele M, Van Geet C, Wouters C, Eggermont E (September 2000). "Reye syndrome revisited: a descriptive term covering a group of heterogeneous disorders". European Journal of Pediatrics. 159 (9): 641–8. doi:10.1007/PL00008399. PMID 11014461.
Reye syndrome is a non-specific descriptive term covering a group of heterogeneous disorders. Moreover, not only the use of acetylsalicylic acid but also of antiemetics is statistically significant in Reye syndrome cases. Both facts weaken the validity of the epidemiological surveys suggesting a link with acetylsalicylic acid.
- Schrör K (2007). "Aspirin and Reye syndrome: a review of the evidence". Paediatric Drugs. 9 (3): 195–204. doi:10.2165/00148581-200709030-00008. PMID 17523700. Archived from the original on 29 June 2011.
The suggestion of a defined cause-effect relationship between aspirin intake and Reye syndrome in children is not supported by sufficient facts. Clearly, no drug treatment is without side effects. Thus, a balanced view of whether treatment with a certain drug is justified in terms of the benefit/risk ratio is always necessary. Aspirin is no exception.
- Macdonald S (November 2002). "Aspirin use to be banned in under 16 year olds". BMJ. 325 (7371): 988c–988. doi:10.1136/bmj.325.7371.988/c. PMC 1169585. PMID 12411346.
Professor Alasdair Breckenridge, said, "There are plenty of analgesic products containing paracetamol and ibuprofen for this age group not associated with Reye's syndrome. There is simply no need to expose those under 16 to the risk—however small."
- "Aspirin and Reye's Syndrome". MHRA. October 2003. Archived from the original on 19 March 2012. Retrieved 17 March 2011.
- Centers for Disease Control (CDC) (June 1982). "Surgeon General's advisory on the use of salicylates and Reye syndrome". MMWR. Morbidity and Mortality Weekly Report. 31 (22): 289–90. PMID 6810083. Archived from the original on 29 June 2011.
- Reye's Syndrome at NINDS "Epidemiologic evidence indicates that aspirin (salicylate) is the major preventable risk factor for Reye's syndrome. The mechanism by which aspirin and other salicylates trigger Reye's syndrome is not completely understood."
- "Measles vaccines: WHO position paper" (PDF). Releve Epidemiologique Hebdomadaire. 84 (35): 349–60. August 2009. PMID 19714924. Archived (PDF) from the original on 19 February 2015.
- "Frequently Asked Questions about Measles". Washington State Department of Health. Retrieved 10 February 2019.
[Vitamin A] cannot prevent or cure the measles
- Huiming Y, Chaomin W, Meng M (October 2005). Yang H (ed.). "Vitamin A for treating measles in children". The Cochrane Database of Systematic Reviews (4): CD001479. doi:10.1002/14651858.CD001479.pub3. PMID 16235283.
- Awotiwon AA, Oduwole O, Sinha A, Okwundu CI (June 2017). "Zinc supplementation for the treatment of measles in children". The Cochrane Database of Systematic Reviews. 6: CD011177. doi:10.1002/14651858.CD011177.pub3. PMC 6481361. PMID 28631310.
- "Measles Complications". Centers for Disease Control and Prevention (CDC). 25 February 2019. Retrieved 14 May 2019.
- Noyce RS, Richardson CD (September 2012). "Nectin 4 is the epithelial cell receptor for measles virus". Trends in Microbiology. 20 (9): 429–39. doi:10.1016/j.tim.2012.05.006. PMID 22721863.
- "NINDS Subacute Sclerosing Panencephalitis Information Page". Archived from the original on 17 October 2014. Retrieved 26 March 2018. "NINDS Subacute Sclerosing Panencephalitis Information Page"
- 14-193b. at Merck Manual of Diagnosis and Therapy Professional Edition
- Centers for Disease Control (CDC) (May 1982). "Recommendation of the Immunization Practices Advisory Committee (ACIP). Measles prevention". MMWR. Morbidity and Mortality Weekly Report. 31 (17): 217–24, 229–31. PMID 6804783.
- Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. (November 2019). "Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens". Science. 366 (6465): 599–606. doi:10.1126/science.aay6485. PMID 31672891. Lay summary.
- Petrova VN, Sawatsky B, Han AX, Laksono BM, Walz L, Parker E, et al. (November 2019). "Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles". Science Immunology. 4 (41): eaay6125. doi:10.1126/sciimmunol.aay6125. PMID 31672862. Lay summary.
- Bartlett, M.S. (1957). "Measles periodicity and community size". J. R. Stat. Soc. Ser. A (120): 48–70.
- Black FL (July 1966). "Measles endemicity in insular populations: critical community size and its evolutionary implication". Journal of Theoretical Biology. 11 (2): 207–11. doi:10.1016/0022-5193(66)90161-5. PMID 5965486.
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. (December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. hdl:10536/DRO/DU:30050819. PMID 23245604.
- "Measles Data and Statistics" (PDF). Retrieved 15 August 2019.
- "Measles notifications and deaths in England and Wales: 1940 to 2017". GOV.UK. Retrieved 1 October 2019.
- "Complications of measles". Centers for Disease Control and Prevention (CDC). 3 November 2014. Archived from the original on 3 January 2015. Retrieved 7 November 2014.
- "Measles". World Health Organization (WHO). 23 July 2013. Archived from the original on 14 August 2013.CS1 maint: unfit url (link)
- "Measles Surveillance Data". World Health Organization (WHO). 17 March 2015. Archived from the original on 3 July 2015.CS1 maint: unfit url (link)
- "Number of Reported Measles Cases with onset date from Nov 2014 to Apr 2015 (6M period)" (PDF). World Health Organization (WHO). Archived from the original on 3 July 2015.CS1 maint: unfit url (link)
- "Reported measles cases and incidence rates by WHO Member States 2013, 2014 as of 11 February 2015" (PDF). World Health Organization (WHO). 7 April 2014. Archived from the original on 3 July 2015.CS1 maint: unfit url (link)
- "Measles—United States, 2005". Centers for Disease Control and Prevention (CDC). 22 December 2006. Archived from the original on 13 March 2015. Retrieved 30 March 2015.
- Greger M (November 2006). "Most and probably all of the distinctive infectious diseases of civilization have been transferred to human populations from animal herds.". Bird Flu: A Virus of Our Own Hatching. Lantern Books. ISBN 1590560981. Archived from the original on 3 October 2009.
- Torrey EF, Yolken RH (3 April 2005). "Their Bugs Are Worse Than Their Bite". The Washington Post. Archived from the original on 11 November 2019. Retrieved 10 November 2019.
- UNICEF Joint Press Release Archived 2015-02-04 at the Wayback Machine
- "Global reductions in measles mortality 2000-2008 and the risk of measles resurgence". Releve Epidemiologique Hebdomadaire. 84 (49): 509–16. December 2009. hdl:10665/241466. PMID 19960624.
- "New measles surveillance data for 2019" (Press release). World Health Organization (WHO). 15 April 2019. Retrieved 4 June 2019.
- Elizabeth Whitman (13 March 2015). "Who Is Stefan Lanka? Court Orders German Measles Denier To Pay 100,000 Euros". International Business Times. Archived from the original on 2 April 2015. Retrieved 31 March 2015.
- "Europe observes a 4-fold increase in measles cases in 2017 compared to previous year". www.euro.who.int (Press release). 19 February 2018. Retrieved 22 February 2018.
- "WHO EpiData" (PDF). World Health Organization (WHO). February 2019. Retrieved 27 March 2019.
- "Measles in Europe: record number of both sick and immunized" (Press release). World Health Organization (WHO). 7 February 2019. Retrieved 27 March 2019.
- "European Region loses ground in effort to eliminate measles". www.euro.who.int (Press release). 29 August 2019. Retrieved 31 August 2019.
- "Region of the Americas is declared free of measles". PAHO. 29 September 2016. Archived from the original on 30 September 2016. Retrieved 30 September 2016.
- "Measles spreads again in the Americas". MercoPress. 28 March 2018. Retrieved 4 July 2018.
- "CDC Media Statement: Measles cases in the U.S. are highest since measles was eliminated in 2000". Centers for Disease Control and Prevention (CDC) (Press release). 26 April 2019.
- Orenstein WA, Papania MJ, Wharton ME (May 2004). "Measles elimination in the United States". The Journal of Infectious Diseases. 189 (Supplement 1): S1–3. doi:10.1086/377693. PMID 15106120.
Figure 1: Reported US measles incidence, 1950–2001.
- Papania MJ, Wallace GS, Rota PA, Icenogle JP, Fiebelkorn AP, Armstrong GL, et al. (February 2014). "Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience". JAMA Pediatrics. 168 (2): 148–55. doi:10.1001/jamapediatrics.2013.4342. PMID 24311021.
- Centers for Disease Control Prevention (CDC) (February 2008). "Multistate measles outbreak associated with an international youth sporting event--Pennsylvania, Michigan, and Texas, August-September 2007". MMWR. Morbidity and Mortality Weekly Report. 57 (7): 169–73. PMID 18288074.
- Gastañaduy PA, Budd J, Fisher N, Redd SB, Fletcher J, Miller J, et al. (October 2016). "A Measles Outbreak in an Underimmunized Amish Community in Ohio". The New England Journal of Medicine. 375 (14): 1343–1354. doi:10.1056/NEJMoa1602295. PMID 27705270.
- "Year in Review: Measles Linked to Disneyland". Archived from the original on 19 May 2017. Retrieved 26 May 2017.
- Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace GS (April 2015). "Measles - United States, January 4-April 2, 2015" (PDF). MMWR. Morbidity and Mortality Weekly Report. 64 (14): 373–6. PMC 5779542. PMID 25879894.
- "Measles kills first patient in 12 years". USA Today. 2 July 2015. Archived from the original on 2 July 2015. Retrieved 2 July 2015.
- "First Measles Death in US Since 2003 Highlights the Unknown Vulnerables – Phenomena: Germination". 2 July 2015. Archived from the original on 3 July 2015. Retrieved 3 July 2015.
- "First Measles Death In 12 Years Renews Vaccination Concerns". NPR. 6 July 2015. Retrieved 23 April 2019.
- "Maine confirms its first case of measles in 20 years". CBC News. Archived from the original on 28 June 2017. Retrieved 28 June 2017.
- "Measles case confirmed in Portland, about 500 people possibly exposed". KATU. Retrieved 3 July 2018.
- "TABLE 1. Weekly cases* of selected infrequently reported notifiable diseases (". wonder.cdc.gov. Retrieved 12 January 2019.
- Alltucker K (11 February 2019). "A quarter of all kindergartners in Washington county aren't immunized. Now there's a measles crisis". USA Today. Retrieved 11 February 2019.
- Howard J (9 January 2019). "New York tackles 'largest measles outbreak' in state's recent history as cases spike globally". CNN. Retrieved 12 January 2019.
- "Washington state is averaging more than one measles case per day in 2019". NBC News. Retrieved 5 February 2019.
- "Amid Measles Outbreak, Anti-Vaxx Parents Have Put Others' Babies At Risk". MSN. Retrieved 5 February 2019.
- Belluz J (27 January 2019). "Washington declared a public health emergency over measles. Thank vaccine-refusing parents". Vox. Retrieved 5 February 2019.
- Gander K (28 January 2019). ""Dangerous" anti-vaxx warning issued by Washington officials as cases in measles outbreak continue to rise". Newsweek. Retrieved 5 February 2019.
- Howard J, Goldschmidt D (24 April 2019). "US measles outbreak is largest since disease was declared eliminated in 2000". CNN. Retrieved 24 April 2019.
- Goldstein-Street J (28 January 2019). "Amid measles outbreak, legislation proposed to ban vaccine exemptions". The Seattle Times. Retrieved 28 January 2019.
- Tanne JH (April 2019). "New York City mayor declares measles public health emergency". BMJ. 365: l1724. doi:10.1136/bmj.l1724. PMID 30971409.
- "Measles Cases and Outbreaks". Centers for Disease Control and Prevention (CDC). 11 October 2019. Archived from the original on 31 October 2019. Retrieved 31 October 2019. This article incorporates text from this source, which is in the public domain.
- Lenharo M (26 July 2016). "Sarampo está eliminado do Brasil, segundo comitê internacional" (in Portuguese). G1. Retrieved 26 July 2016.
- "Sarampo está eliminado do Brasil, segundo comitê internacional". Bem Estar (in Portuguese). 26 July 2016.
- "Brasil já tem mais de mil casos de sarampo em 2018, segundo Ministério da Saúde". G1 (in Portuguese).
- Saúde Md. "Ministério da Saúde atualiza casos de sarampo". portalms.saude.gov.br (in Portuguese). Retrieved 2 August 2018.
- Lien Chau (18 April 2014). "Vietnam minister calls for calm in face of 8,500 measles cases, 114 fatalities". Thanh Niên. Archived from the original on 18 April 2014. Retrieved 19 April 2014.
- Quốc Thanh (30 May 2014). "Bộ Y tế: "VN đã phản ứng rất nhanh đối với dịch sởi"" [Ministry of Health: "Vietnam has responded very quickly to measles"] (in Vietnamese). Tuổi Trẻ. Archived from the original on 31 May 2014. Retrieved 19 April 2014.
- "WHO doctors in Myanmar's Naga areas identify 'mystery disease'". Eastern Mirror Nagaland. 6 August 2016. Archived from the original on 19 August 2017. Retrieved 8 August 2016.
- "Myanmar (02): (SA) fatal, measles confirmed". www.promedmail.org (Archive Number: 20160806.4398118). International Society for Infectious Diseases. Archived from the original on 20 August 2016. Retrieved 8 August 2016.
- "Philippines measles update: Nearly 600 cases in 2 days". Outbreak News Today. 26 March 2019. Archived from the original on 30 August 2019. Retrieved 30 August 2019.
- Alyssa J. Oon (17 June 2019). "A Measles Outbreak Is The Cause of 15 Orang Asli Deaths In Kelantan". Says.com. Archived from the original on 27 August 2019. Retrieved 30 August 2019.
- Rachel Tay (18 June 2019). "The mysterious illness that caused 15 deaths in a Malaysian tribe has been linked to a measles outbreak". Business Insider Malaysia. Archived from the original on 30 August 2019. Retrieved 30 August 2019.
- Furuse Y, Suzuki A, Oshitani H (March 2010). "Origin of measles virus: divergence from rinderpest virus between the 11th and 12th centuries". Virology Journal. 7: 52. doi:10.1186/1743-422X-7-52. PMC 2838858. PMID 20202190.
- Cohen SG (February 2008). "Measles and immunomodulation". The Journal of Allergy and Clinical Immunology. 121 (2): 543–4. doi:10.1016/j.jaci.2007.12.1152. PMID 18269930.
- "Maurice R. Hilleman Dies; Created Vaccines Archived 2012-10-20 at the Wayback Machine". The Washington Post. 13 April 2005.
- Byrne JP (2008). Encyclopedia of Pestilence, Pandemics, and Plagues: A–M. ABC-CLIO. p. 413. ISBN 978-0-313-34102-1. Archived from the original on 13 November 2013.
- Migration and Disease. Digital History.
- "Fiji School of Medicine". Archived from the original on 10 April 2015.CS1 maint: unfit url (link)
- Bhaumik S (16 May 2006). "Measles hits rare Andaman tribe". BBC News Online. Archived from the original on 23 August 2011.
- "Live attenuated measles vaccine". EPI Newsletter. 2 (1): 6. February 1980. PMID 12314356.
- Rima BK, Earle JA, Yeo RP, Herlihy L, Baczko K, ter Meulen V, et al. (May 1995). "Temporal and geographical distribution of measles virus genotypes". The Journal of General Virology. 76 ( Pt 5) (5): 1173–80. doi:10.1099/0022-1317-76-5-1173. PMID 7730801.
- Offit PA (2007). Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases. Washington, DC: Smithsonian. ISBN 978-0-06-122796-7.
- "Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP) Archived 2012-05-15 at the Wayback Machine". Centers for Disease Control and Prevention (CDC).
- "Measles: Questions and Answers" (PDF). Immunization Action Coalition. Archived from the original on 24 January 2013.CS1 maint: unfit url (link)
- "Measles Frequently Asked Questions about Measles in U.S". Centers for Disease Control and Prevention (CDC). 28 August 2018.
- Stefan Lanka (April 1995). "HIV; Reality or artefact?". Virusmyth.com. Archived from the original on 26 March 2015. Retrieved 31 March 2015.
- "Das Masern-Virus 100.000 € Belohnung! WANTeD Der Durchmesser" (PDF) (in German). 24 November 2011. Archived (PDF) from the original on 2 April 2015. Retrieved 31 March 2015.
- "Germany court orders measles sceptic to pay 100,000 euros". BBC News Online. 12 March 2015. Archived from the original on 31 March 2015. Retrieved 31 March 2015.
- Steven Novella (13 March 2015). "Yes, Dr. Lanka, Measles is Real". NeuroLogica Blog. Archived from the original on 31 March 2015. Retrieved 31 March 2015.
- Abramson B (2018). Vaccine, vaccination, and immunization law. Bloomberg Law. pp. 10–30. ISBN 9781682675830.
- Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT (May 2015). "Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality". Science. 348 (6235): 694–9. Bibcode:2015Sci...348..694M. doi:10.1126/science.aaa3662. PMC 4823017. PMID 25954009. Lay summary.
- White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, et al. (July 2007). "Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity". Antimicrobial Agents and Chemotherapy. 51 (7): 2293–303. doi:10.1128/AAC.00289-07. PMC 1913224. PMID 17470652.
- Krumm SA, Yan D, Hovingh ES, Evers TJ, Enkirch T, Reddy GP, et al. (April 2014). "An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model". Science Translational Medicine. 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMC 4080709. PMID 24739760.
- "The measles virus is highly infectious, but rarely deadly". NewScientist.com. Archived from the original on 5 February 2017. Retrieved 5 February 2017.
|Wikiquote has quotations related to: Measles|
|Wikimedia Commons has media related to Measles.|